New studies reveal rare but real risk of GLP-1 drugs
Health New studies reveal rare but real risk of GLP-1 drugs By Reuters Published July 23, 2026, 10:46 a.m. Add The New York Post on Google July 22 (Reuters) – The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest. At two or more years after starting treatment, the odds of a new diagnosis of alopecia in GLP-1 users were 37 percent higher than in users of so-called SGLT-2 drugs and 68 percent higher versus DPP-4 drugs, researchers at the University of Pennsylvania reported on Wednesday in The BMJ.
- ▪Health New studies reveal rare but real risk of GLP-1 drugs By Reuters Published July 23, 2026, 10:46 a.m.
- ▪Add The New York Post on Google July 22 (Reuters) – The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.
- ▪At two or more years after starting treatment, the odds of a new diagnosis of alopecia in GLP-1 users were 37 percent higher than in users of so-called SGLT-2 drugs and 68 percent higher versus DPP-4 drugs, researchers at the University o
New York Post files mainly under news. We currently carry 11,037 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | New York Post |
| Canonical URL | https://nypost.com/2026/07/23/health/new-studies-reveal-rare-but-real-risk-of-glp-1-drugs/ |
| Publication time | Thu, 23 Jul 2026 10:46:39 -0400 |
| Retrieval time | 2026-07-23T14:51:52.237Z |
| Last seen | 2026-07-23T14:51:52.237Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | B6Cvc4Pk_TMH |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Health New studies reveal rare but real risk of GLP-1 drugs By Reuters Published July 23, 2026, 10:46 a.m. ET (function() { var overlay = document.getElementById("nyp-player-lcp-overlay"); if (!overlay) { return; } function hideOverlay() { overlay.remove(); } function afterDCL() { requestAnimationFrame(hideOverlay); } if (document.readyState === "loading") { document.addEventListener("DOMContentLoaded", afterDCL, { once: true }); } else { afterDCL(); } })(); See more of our coverage in your search results. Add The New York Post on Google July 22 (Reuters) – The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at New York Post.
Discussion
0 commentsMore from New York Post
